RAD51AP2, a novel vertebrate- and meiotic-specific protein, shares a conserved RAD51-interacting C-terminal domain with RAD51AP1/PIR51 by Kovalenko, Oleg V. et al.
RAD51AP2, a novel vertebrate- and meiotic-specific
protein, shares a conserved RAD51-interacting
C-terminal domain with RAD51AP1/PIR51
Oleg V. Kovalenko, Claudia Wiese
1 and David Schild
1,*
DepartmentofMedicalOncology,Dana-FarberCancerInstitute,Boston,MA,02115,USAand
1LifeSciencesDivision,
Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
Received July 25, 2006; Revised August 25, 2006; Accepted August 27, 2006
ABSTRACT
Many interacting proteins regulate and/or assist
the activities of RAD51, a recombinase which
plays a critical role in both DNA repair and meiotic
recombination. Yeast two-hybrid screening of a
human testis cDNA library revealed a new protein,
RAD51AP2 (RAD51 Associated Protein 2), that
interacts strongly with RAD51. A full-length cDNA
clone predicts a novel vertebrate-specific protein of
1159 residues, and the RAD51AP2 transcript was
observed only in meiotic tissue (i.e. adult testis
and fetal ovary), suggesting a meiotic-specific
function for RAD51AP2. In HEK293 cells the inter-
action of RAD51 with an ectopically-expressed
recombinant large fragment of RAD51AP2 requires
the C-terminal 57 residues of RAD51AP2. This
RAD51-binding region shows 81% homology to the
C-terminus of RAD51AP1/PIR51, an otherwise totally
unrelated RAD51-binding partner that is ubiqui-
tously expressed. Analyses using truncations and
point mutations in both RAD51AP1 and RAD51AP2
demonstrate that these proteins use the same struc-
tural motif for RAD51 binding. RAD54 shares some
homology with this RAD51-binding motif, but this
homologous region plays only an accessory role to
the adjacent main RAD51-interacting region, which
has been narrowed here to 40 amino acids. A novel
protein, RAD51AP2, has been discovered that inter-
acts with RAD51 through a C-terminal motif also
present in RAD51AP1.
INTRODUCTION
The eukaryotic RAD51 gene was ﬁrst identiﬁed in baker’s
yeast through analysis of mutations that result in recombina-
tion deﬁciency and sensitivity to DNA-damaging agents (1).
Genetic studies in yeast demonstrated that the RAD51 protein
plays a prominent role in both mitotic and meiotic recombi-
nation, and in DNA repair (2–5). In meiosis, RAD51 is
thought to promote homologous chromosome synapsis and
interhomolog recombination (6–8). Sequence and structural
analysis of the yeast and mammalian RAD51 proteins
revealed extensive similarity to the key bacterial recombinase
RecA. The extensive biochemical analysis of yeast and
human RAD51 proteins highlighted the functional similarities
between these proteins and the RecA protein (9–12). The
RAD51 gene in vertebrates has been shown to be essential
for cell proliferation. Mice with a targeted disruption of
the RAD51 gene die early during embryogenesis (13,14).
Furthermore, repression of human RAD51 is lethal in a
chicken rad51
 /  DT40 cell lines expressing an inducible
HsRAD51, probably due to the accumulation of chromosome
breaks, supporting a role for HsRAD51 in the repair of DNA
breaks arising during replication (15).
The normal activity of RAD51, both in homologous
recombinational DNA repair in mitotic cells and in meiotic
recombination, necessitates its physical interactions with a
number of other proteins. Indeed, mammalian RAD51 has
been shown to interact in vitro and/or in vivo with the
recombination proteins RAD52 and RAD54 (16,17), the
tumor suppressors TP53 and BRCA2 (18–23), the protein
kinase c-ABL (24,25), the SUMO-1-conjugating enzyme
UBC9 (26–28), the RAD51 paralogs XRCC3 and RAD51C
(29,30), MDC1 (mediator of DNA damage checkpoint)
(31), RPA (replication protein A) (32,33), CHK1 (34), nucle-
olin (35) and several other proteins [for review see (12,36)].
The interactions of RAD51 with TP53, RPA and the BRC
repeats of BRCA2 are relatively well understood (see Discus-
sion). Much remains to be learned about other RAD51
protein–protein interactions, and clearly further biochemical
and genetic analyses of these interactions will facilitate our
understanding of the function and regulation of the RAD51
protein.
In a previous study, we identiﬁed a novel RAD51-
interacting protein, RAD51AP1/PIR51 through a yeast
two-hybrid (Y2H) human cDNA library screen (37). (Please
note: the HUGO committee on nomenclature has renamed
PIR51 as RAD51AP1 for RAD51 Associated Protein 1.)
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identiﬁed the mouse Rad51ap1 homolog (originally called
Rab22). The interaction of human and mouse RAD51AP1
with RAD51 was conﬁrmed by in vitro experiments, and
in vivo co-localization of mouse RAD51AP1 to RAD51
foci was shown using ectopical overexpression of tagged con-
structs (19,37). In the current study, we present data on the
identiﬁcation of another novel human protein, RAD51AP2
(RAD51 Associated Protein 2), which interacts strongly and
speciﬁcally with human RAD51. Interestingly, human
RAD51AP2 expression is detected only in adult testis and
fetal ovary, which suggests that its gene product may play
a role in RAD51-mediated meiotic recombination. Moreover,
we have identiﬁed a common motif present in both
RAD51AP2 and RAD51AP1 that mediates their interaction
with RAD51. A sequence that shares some homology with
this motif is also present in the RAD54 protein, but seems
to play at most only a minor role in the interaction of
RAD54 with RAD51.
MATERIALS AND METHODS
Two-hybrid system
The Gal4-based Y2H system was essentially as described pre-
viously (37). All the vectors and yeast strains were obtained
from Clontech. To screen for RAD51-interacting proteins, a
human testis cDNA library in vector pACT2 was used.
Yeast strain HF7c was ﬁrst transformed with a RAD51 bait
construct, pEG918, followed by the library DNA. Interacting
clones were selected as His
+ transformants, and were subse-
quently tested for activation of lacZ reporter in strain
SFY526. The clone containing the partial RAD51AP2 gene
sequence, whose protein product interacts with RAD51,
was designated p23-1. Vectors pGBT9 and pGADGH
were used to make additional two-hybrid constructs for
human RAD51AP1, RAD51AP2, RAD54 and DMC1, and
for Saccharomyces cerevisiae RAD51. Vector pGBKT7
was used to make the RAD51AP2-C33 construct for the
experiment in Figure 5C. For Y2H analyses of some of the
RAD51AP1 and RAD51AP2 mutants and for the RAD54
truncation analyses, the yeast strain Y190-ura
  was used
(29). The QuikChange II Site-directed Mutagenesis Kit
(Stratagene) was used for mutagenesis, and each mutated/
truncated construct was sequenced across the complete insert.
Cloning of the full-length RAD51AP2 ORF
To amplify the full length RAD51AP2 open reading frame
(ORF), primers were designed from the 50-untranslated region
(50-UTR) (50-GCGGAATTCGACAGATCCTTTCCATTCG-
CTGTC-30; the underlined EcoRI site was added for sub-
cloning) and from the 30-UTR (50-CGCGGATCCATGCCC-
CAAACCCCCAAGCTGGAAGAAC-30; the underlined
BamHI site was added for subcloning). GenBank contains
three expressed sequence tag (EST) clones (loci DB088408,
DB096210 and DB449196) that are reported to be full length
and have sequence data from the 50 end of the RAD51AP2
cDNA. Since these clones were not available, we used their
partial GenBank sequence data from the 50-end and our
own DNA sequence data for the 30-end to design primers to
amplify the entire ORF from Marathon-Ready total cDNA
from human testis (Clontech). Since no PCR product was
observed using these two primers, two additional internal
primers were designed for use in combination with the
original primers to separately amplify the 50-region and the
30-region of the RAD51AP2 ORF (50-CGTAACTGTCCAGA-
CATTCTGCTTCCTCCC-30 was used in combination with
the original 50 primer, and 50-GAAAATGACTACCCATCA-
CTCAGTAGCC-30 was used in combination with the original
30 primer). PCR was performed with high-ﬁdelity Pfu DNA
polymerase (Stratagene) using 30 cycles. The resulting two
PCR products overlap by  100 bp, and each product includes
the unique PstI site in the middle of the RAD51AP2 ORF.
Following restriction digestion, the EcoRI to PstI fragment
from the 50-end and the PstI to BamHI fragment from the
30-end were each subcloned into the EcoRI to BamHI
sites of a single pBluescript SK+ vector, reconstituting the
full-length RAD51AP2 ORF. The complete DNA sequence
of the insert in this plasmid (pDS443) was determined for
both stands.
Northern analysis of the RAD51AP2 expression
A human multiple tissue Northern blot II (Clontech) was used
to analyze RAD51AP2 messenger RNA (mRNA) expression.
The sequence of the RAD51AP2 insert in clone p23-1 was
ampliﬁed by PCR. The resulting fragment was labeled with
a-
32P-dCTP by random priming and used as the hybridization
probe following conditions suggested by Clontech.
PCR analysis of RAD51AP1 and RAD51AP2 transcripts
in different human tissues
PCR was used to determine if the RAD51AP1 and
RAD51AP2 transcripts are present in cDNA samples from
16 different adult human tissues (Clontech), 5 different
fetal human tissues (BioChain) and 7 different human cell
lines (Clontech). The PCR primers used for RAD51AP1
were AP1-50:5 0GATGACAAGCTCTACCAGAGAGAC30
and AP1-30:5 0CTTGCTTTCAGCTGAAGGACTGCG30 and
these amplify a 630 bp fragment. The primers for
RAD51AP2 were AP2-50:5 0CTGGTCTGAGTGAAGG-
GAATGATG30 and AP2-30:5 0GCGGTCGTACTCTTGAA-
ATGCCATG30, and these amplify a 570 bp fragment. For
each primer pair, the two different primers were from
different exons, thus avoiding the possible problems with
contaminating genomic DNA, since this DNA would result
in a much larger PCR product. PCR was performed using
Taq polymerase, with 35 cycles of 50 C6 0s ,7 2  C 120 s
and 94 C6 0s .
Interaction of RAD51 and RAD51AP2 proteins
in mammalian cells
To produce a RAD51AP2 protein fragment in mammalian
cells, the sequence encoding the 293-amino acid
RAD51AP2 polypeptide from p23-1 was subcloned into vec-
tor pCGT (obtained from Dr H. Zhang, Yale University) as a
fusion with a T7 epitope, producing plasmid pOK80. Also,
RAD51AP2-C293 sequence lacking its last 57 amino acids
(RAD51AP2-DC57) was cloned into pCGT, producing plas-
mid pOK90. Fortuitously, the vector pCGT used for cloning
contained the sequence of human herpesvirus Vmw65
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placed the inserts upstream of the Vmw65 sequences, effec-
tively eliminating expression of the latter. Thus, when used as
a control in transfection experiments, vector pCGT produced
the T7-tagged 65 kDa Vmw65 polypeptide, whereas plasmids
pOK80 and pOK90 produced only the expected T7-tagged
RAD51AP2 protein fragments.
For transient transfection and co-immunoprecipitation
experiments, pCGT, pOK80 and pOK90 were introduced
into cultured human HEK293 cells using the calcium
phosphate procedure, and cells were incubated for 36 h. In
some experiments, DNA damage was introduced to trans-
fected cells 3 h before the cells were harvested by adding
100 mg/ml methylmethane sulfonate or 0.5 mg/ml mitomycin
C to the medium. As a control, cycloheximide, a protein syn-
thesis inhibitor, was added at 10 mg/ml in these experiments.
After harvest, cells were lysed in buffer containing 20 mM
Na-phosphate (pH 7.4), 150 mM NaCl, 0.5% NP-40, and a
cocktail of protease inhibitors (Roche) for 20 min on ice.
Lysates were used for immunoprecipitation with monoclonal
antibody directed against the T7 tag (Novagene) followed
by protein A-agarose beads. The beads were washed
several times with lysis buffer and the immunoprecipitated
material was analyzed by SDS–PAGE followed by immuno-
blotting with anti-T7 and anti-RAD51 antibodies. Secondary
anti-mouse or anti-rabbit antibodies were conjugated with
alkaline phosphatase, and detection was carried out with
NBT (nitroblue tetrazolium chloride) and BCIP (5-bromo-4-
chloro-3-indolylphosphate p-toluidine salt) chromogenic sub-
strates (Life Technologies), or with the more sensitive
Renaissance  chemiluminescence reagent (NEN Life Science
Products). Bands produced on an X-ray ﬁlm after chemilumi-
nescence detection were scanned and quantitated using a
Molecular Dynamics densitometer.
RESULTS
Isolation of the human RAD51AP2 gene
Using the human RAD51 protein as a bait, a Y2H screen of a
human testis cDNA library resulted in the isolation of an
 1.2 kbp insert encoding 321 amino acids, a stop codon
and a 30-UTR (clone p23-1). The complete ORF was PCR
ampliﬁed as two overlapping fragments (see Material and
Methods). The two PCR products were used to reconstruct
the full-length ORF, which was cloned into pBluescript
SK+ and sequenced (GenBank accession # DQ860102).
This sequence data shows that this ORF is predicted to
encode a protein of 1159 amino acids, and its C-terminus is
identical to our Clone p23-1. We have named this protein
RAD51AP2 (RAD51 Associated Protein 2) (Figure 1B).
Comparing the ORF sequence with the genomic sequence
indicates that RAD51AP2 maps to human chromosome 2
and the ORF consists of three exons, one very large one
encoding 1083 amino acids, followed by two much smaller
ones encoding 27 amino acids and 49 amino acids
(Figure 1A). Our DNA and predicted amino acids sequence
data are completely consistent with a GenBank hypothetic
cDNA (XM_496545) and protein (XP_496545).
Sequence analysis of the mouse genome predicts a
homologous protein of 976 amino acids (GenBank
XP_147640; the predicted cDNA XM_147640 maps to
mouse chromosome 12). The sequence alignment of the
predicted human and mouse homologs indicates that the
human protein has an extra region of 154 amino acids in
the middle of exon 1 (underlined in Figure 1B). This extra
region does not appear to be an extra unexcised intron,
since it does not have a sequence resembling the consensus
for a splice junction, and this extra 154 amino acids
region is also present in the genomic sequence of Pan
troglodytes (chimpanzee) (data not shown). Even the Rattus
novegicus genomic sequence is only missing 45 of the
154 amino acids compared to the human protein. At the
very C-terminus the human and chimpanzee proteins also
encode 11 amino acids that are not present in either the
mouse or rat protein. GenBank also contains a partial
sequence of a Gallus gallus (chicken) homolog that also
appears to be missing the 11 amino acids at the C-terminus
(Figure 5A).
Figure 1. Structure of the human RAD51AP2 gene, and sequence of the
human RAD51AP2 proteins. (A) Comparing the cDNA sequence we have
determined with the genomic sequence in GenBank, it was determined that
RAD51AP2 consists of one very long exon followed by two short exons, the
last of which completely encodes the RAD51-interacting domain. (B) The
amino acid sequence of the entire human RAD51AP2 proteins predicted from
our RAD51AP2 cDNA sequence (GenBank accession # DQ860102).
Residues similar to a Walker A-type nucleotide-binding motif in human
RAD51AP2 are in the light gray box. The long underlined region is missing
in the mouse homolog, and the short black boxed residues are the two
boundaries among the amino acids encoded by the three exons. The
C-terminal 33 amino acids (C33) in the red box are sufficient for
RAD51-interaction in the Y2H system.
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RAD51AP2 shows no signiﬁcant overall homology to any
other protein in the GenBank, and has no apparent protein
motifs, except for a sequence Ala-xxxx-Gly-Lys-Ser in the
C-terminus that resembles the Walker A-type nucleotide
binding motif (consensus Ala/Gly-xxxx-Gly-Lys-Thr/Ser),
but RAD51AP2 lacks any obvious Walker B motif. The
mouse, rat and partial chicken RAD51AP2 homologs all
lack any sequence similar to a Walker A or B motif. Although
the human RAD51AP2 protein lacks any other apparent pro-
tein motif, the C-terminal region does show some interesting
properties. This region is positively charged: among the last
55 residues, there are 7 arginines, 5 lysines and 3 histidines,
with only one single negatively charged residue (glutamic
acid). In addition the C-terminal region shares homology
with RAD51AP1 (presented below).
RAD51AP2 gene expression occurs in meiotic tissue only
Northern analysis of RAD51AP2 gene expression was per-
formed using a panel of human mRNAs from various organs.
A strong hybridization signal was detected only in testis, with
no signal present in thymus, spleen, prostate, uterus, colon,
small intestine, and peripheral blood leukocytes (Figure 2).
The size of the hybridizing transcript is   4.2 kb, which is
long enough that it could accommodate the size of the
RAD51AP2 ORF described above. The meiotic speciﬁcity
of RAD51AP2 gene expression is supported by our PCR
analysis, as we were not able to amplify any RAD51AP2
sequences from cDNA sources other than adult human testis
and fetal ovary. No PCR product was observed in 15
additional human tissues, or 4 additional fetal tissues
(Figure 3A and B, and additional data not shown for adult
brain, heart, kidney, liver, lung, pancreas, placenta and skel-
etal muscle). No PCR product was observed with seven
human cell lines (HEK293, SKOV-3, Saos2, A431, Du145,
H1299 and MCF7) (data not shown). As a control, a PCR
product from the RAD51AP1/PIR51 transcript was ampliﬁed,
and shown to be present in each of these same human 16
adult tissues, 5 fetal tissues and 7 cell lines (Figure 3C–E
and additional data not shown). It should be noted that 35
PCR cycles were used to ensure that even rare transcripts
would be ampliﬁed. This data can be used to determine if a
transcript is present in a sample, but can not be used to quant-
ify the transcript level, if it is present.
Information about the expression of new genes can also
be obtained by examining the EST database at GenBank,
which includes sequences from different cDNA libraries.
There are currently only 11 human EST clones in the data-
base with sequence identity to parts of RAD51AP2. Six
EST clones are from testis libraries, including three that
appear to encode the 50-end (see Materials and Methods),
and another EST clone was isolated from a germ cell
tumor. The remaining four are from the Athersys RAGE
(random activation of gene expression) library constructed
by using specialized integration vectors that result in the
artiﬁcial transcription of even normally silenced genes (38).
Therefore, data from the EST database is consistent with
expression of RAD51AP2 in testis and germ cells, with no
expression in mitotic tissues. On the other hand, the EST
database has numerous RAD51AP1 EST clones from many
different human tissues, supporting the ubiquitous expression
of this gene.
RAD51AP2 is not expressed in mitotic cells even after
DNA damage
Although expression of RAD51AP2 was not observed in
mitotic cells, it seemed possible that this transcript might
be induced by DNA damage. However, treatment of human
osteosarcoma-derived U2OS cells (from ATCC) with 2 Gy
X-rays still resulted in no RAD51AP2 transcript
(Figure 3F), and the same result was also observed using
HeLa cells (data not shown).
Interaction of RAD51AP2 protein with RAD51 in the
Y2H system
The 321-amino acids RAD51AP2 fragment was subcloned
from p23-1 into two-hybrid vectors as fusions with the
DNA-binding (DBD) and activation domain (AD) of Gal4,
to reconﬁrm the interaction with human RAD51 and to
test for possible additional interactions. When fused to
Gal4-AD, RAD51AP2-C321 (containing the C-terminal 321
amino acids) showed strong and speciﬁc interaction with
RAD51 (Table 1). No interaction was observed with human
DMC1 or the yeast RAD51 protein, both highly homologous
to human RAD51, or with human RAD51AP1, another
Figure 2. Northern blot analysis of the RAD51AP2 gene in human tissues.
Lanes contain  2 mg of poly A
+ RNA from the human tissues indicated. PBL,
peripheral blood leukocytes; SI, small intestine. Upper panel, hybridization
with RAD51AP2 cDNA probe. Lower panel, hybridization with human b-
actin cDNA probe. The positions of RNA size markers, in kilobases, are
indicated on the right.
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interaction with human UBC9, lamin C or mouse p53 protein
was found (data not shown). The RAD51-interaction is medi-
ated by the extreme C-terminus of RAD51AP2-C321. The
RAD51AP2-C321 protein in which the last 57 residues are
deleted (designated as RAD51AP2-DC57) fails to interact
with RAD51. In addition, the last 92 amino acids of
RAD51AP2 (C92) are sufﬁcient for a strong interaction
with RAD51, although at only  48% of the strength of the
321 amino acid fragment (Table 1). In light of our results
on RAD51AP2-DC57, it seems likely that the decreased
strength of the RAD51AP2-C92 interaction is due to reduced
stability of this shorter fusion or masking of the interacting
region, although we can not rule out the possibility that
additional residues outside of the last 92 amino acids of
RAD51AP2 are necessary for full interaction with RAD51.
When present as a fusion with Gal4-DBD in a yeast reporter
strain, the 321 amino acid RAD51AP2 polypeptide weakly
activates transcription of lacZ gene on its own (3–5 units of
b-gal; data not shown). Since the RAD51AP2-C92 fragment
retains the RAD51 interaction capability in the two-hybrid
system and has no transcription activation ability of its
own, it was used in all subsequent two-hybrid studies as a
Gal4-DBD fusion of RAD51AP2. The original cloned 321
amino acid RAD51AP2 encoding sequence was used as a
Gal4-AD fusion.
The full length RAD51AP2 ORF and three long C-terminal
fragments (C661, C830 and C661) were also cloned into the
Figure 3. PCR analysis showing meiotic-specific expression of human RAD51AP2 in adult testis and fetal ovary, but ubiquitous expression of RAD51AP1.
(A) RAD51AP2 (AP2 in figure) transcript in human adult tissues (note: RAD51AP2 is top band in testis sample only and PCR primers are the bottom bands).
LC—leukocytes, SI—small intestine. The size and approximate mobility (based on size standards) of the PCR products are indicated at the right side of each
panel. (B) RAD51AP2 transcripts in human fetal tissues. (C and D) RAD51AP1 (AP1 in figure) transcript in human adult tissues. SM—smooth muscle.
(E) RAD51AP1 transcripts in human fetal tissues. Note: RAD51AP1 has multiple variants in adult testis and fetal ovary. (B–E) DNA size markers (400 and
800 bp) in right lane. (F) RAD51AP2 transcript is not induced in U20S cells exposed to 2 Gy X-rays. End-point RT–PCR was carried out from 1st strand cDNA
samples in a multiplex PCR reaction amplifying both a 838 bp product for b-actin and a 570 bp product for RAD51AP2 (as in A and B). A product for RAD51AP2
was not obtained (as indicated by the absence of a 570 bp fragment). DNA size markers (1200, 800 and 400 bp) in right lane. (G) Same samples as in F:
End-point RT–PCR for b-actin and GADD45A (171 bp positive control for the induction of transcript after X-rays). DNA size markers (2000, 1200, and 800 bp in
top panel, and 200 and 100 bp in bottom panel) in right lane.
Table 1. Specific interaction of RAD51AP2 with RAD51 in the two-hybrid system is mediated by the carboxy-terminus of RAD51AP2
Gal4 DBD
a plasmid Gal4 AD plasmid Gal4 DBD protein fusion Gal4 AD protein fusion Units of b-galactosidase
pEG918 pOK42 RAD51 RAD51AP2-C321 300.9
pOK21 pOK42 DMC1 RAD51AP2-C321 <0.3
pEG978 pOK42 ScRAD51 RAD51AP2-C321 <0.3
pOK31 pOK42 RAD51AP1 RAD51AP2-C321 <0.3
pEG918 pOK77 RAD51 RAD51AP2-DC57
b <0.5
pEG918 pOK40 RAD51 RAD51AP2-C92 143.4
aDBD and AD stand for the DNA-binding and activation domain of Gal4, respectively. The units of b-galactosidase are average values from at least four liquid
cultures. All inserts are human except ScRAD51, which is from yeast.
bThis plasmid actually only encodes the C321 fragment deleted for the last 57 amino acids, and similarly in Table 2.
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RAD51. All four interacted with RAD51, although more
weakly then the C321 fragment, and the longer the protein/
fragment, the weaker the interaction (data not shown). Our
favored interpretation of this data is that the full-length
1159 amino acid human RAD51AP2 protein is probably
not stably expressed at a very high level in yeast, and even
the shorter fragments are not expressed well, although better
then the full-length protein. An alternative interpretation is
that longer fragments of RAD51AP2 contain regions that
mask the interaction of RAD51AP2 with RAD51, at least
in the Y2H system. Full-length RAD51AP2 and the three
truncations were also tested for interaction with human
DMC1, but no interaction was observed (data not shown).
Ectopically expressed RAD51AP2 interacts with
RAD51 in human mitotic cells
To test if the RAD51-RAD51AP2 interaction could occur
in vivo, the 293 amino acid RAD51AP2 polypeptide
(RAD51AP2-C293) or its C-terminally truncated derivative
(RAD51AP2-DC57), both tagged with the T7 epitope, were
transiently overexpressed in HEK293 cells, and immuno-
precipitation with anti-T7 antibody was carried out
(Figure 4A). A fraction of endogenous RAD51 protein
readily co-precipitated with RAD51AP2-C293, but not with
RAD51AP2-DC57 or with a control protein (Figure 4A,
lanes 7–9). This result further stresses the importance of the
extreme C-terminus of RAD51AP2 for the interaction and
provides evidence that when recombinant RAD51AP2 is
ectopically expressed in mitotic human cells it can associate
with RAD51.
Next, we asked whether the RAD51-RAD51AP2 inter-
action in human cells could be modulated in response to
DNA damage. To test this, RAD51AP2-C293 was transiently
overexpressed in HEK293 cells as described above, and DNA
damage was introduced by adding methyl methanesulfonate
(MMS) or mitomycin C (MMC) 3 h before harvesting
cells for co-IP analysis (Figure 4B). Results from three
independent experiments indicate that co-precipitation of
RAD51 with RAD51AP2-C293 is stimulated  7- and  17-
fold by MMS or MMC treatment, respectively (Figure 4B,
lanes 5–7; and 4C). Previously, it was shown that these
agents, at the concentrations used, induce formation of
nuclear RAD51 foci in a number of mammalian cell lines,
with up to 60% of cells being stained with anti-RAD51 anti-
body (39,40). These foci presumably mark sites where
RAD51-dependent repair of DNA damage takes place. In
contrast, cycloheximide, a protein synthesis inhibitor, does
not induce RAD51 foci (40) and does not affect signiﬁcantly
co-precipitation of RAD51 with RAD51AP2-C293
(Figure 4B, lane 8; and 4C). Although DNA damage
increases the interaction between these two proteins, we do
not feel that RAD51AP2 is involved in DNA repair since it
is not expressed in mitotic cells (see Discussion).
RAD51AP2 and RAD51AP1 share a common
C-terminal motif necessary for interaction with RAD51
Examination of the sequence of the RAD51AP2 C-terminus
revealed an intriguing homology with RAD51AP1, a protein
we previously isolated because of its interaction with human
RAD51 (37). The homology between RAD51AP2 and
RAD51AP1 spans a region of 35 amino acids located near
the C-terminus of the two proteins (Figure 5A), and in this
region, 14 amino acids are identical between the two
Figure 4. RAD51AP2 and RAD51 proteins interact in human cells, and the
interaction is enhanced by DNA damage. (A) Human HEK293 cells were
transiently transfected with plasmids encoding the following T7 epitope-
tagged proteins: Vmw65 protein of herpesvirus (lane 1); 293amino acid
RAD51AP2 polypeptide (lane 2); RAD51AP2 protein deleted for its last 57
residues (lane 3). Immunoprecipitation with anti-T7 antibody followed by
protein A-agarose beads was carried out, and fractions of cell lysates before
IP, supernatant of IP, and IP pellets were analyzed by Western blotting using
anti-T7 (top panel) or anti-RAD51 antibody (lower panel). Secondary
antibodies were conjugated to alkaline phosphatase, which was detected using
chromogenic substrates. (B) Transfection with plasmid encoding the 293
amino acid RAD51AP2 polypeptide was performed as in panel A, and
0.5 mg/ml MMC, 100 mg/ml MMS or 10 mg/ml cycloheximide (Cyc.) was
added to individual cultures 3 h before harvesting cells for IP. IP and Western
blotting were done as in panel A, except that chemiluminescent substrates
were used to detect peroxidase conjugated to secondary antibodies. To
facilitate the relative comparison of RAD51 signals from IP pellets (shown in
panel C), the amount of these fractions loaded on the gel was adjusted in an
effort to get similar intensities of the T7-tagged RAD51AP2 signal in each
lane. The residual differences were normalized to the control (untreated cells)
for comparison of the amounts of RAD51 that coprecipitated with
RAD51AP2. (C) Quantitation of RAD51-RAD51AP2 coimmunoprecipitation
from panel B. The signals from precipitated RAD51 in IP pellet fractions
were measured using a densitometer and then normalized for the signal from
anti-T7 analysis of the same fractions. The relative increase of RAD51 signal
from treated cells as compared to the signal observed from untreated cells
(artificially set at 1.0 in left lane) is shown.
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strongest homology is the 16 amino acids C-terminal part
of the region encompassing 11 identical and 3 highly con-
served residues between RAD51AP1 and RAD51AP2. It is
important to note that RAD51AP1 and RAD51AP2 are of
very different sizes (335 and 1159 amino acids, respectively)
and that these proteins share not other regions of homology.
Deletion analysis was used to further map the region of
RAD51AP2 responsible for the interaction with RAD51
(Table 2). As mentioned above, deletion of the last
57 amino acids of RAD51AP2 (RAD51AP2-DC57)
completely eliminates interaction with RAD51 in yeast and
human cells. In contrast, the 92 and 33 amino acids
C-terminal fragments of RAD51AP2 show strong two-hybrid
interaction with RAD51, in particular when fused to Gal4-
DBD (Table 2). This result indicates that a small region at
the very end of the cloned RAD51AP2 sequence is its
primary site responsible for interaction with RAD51.
As shown above, RAD51AP2 is homologous in its
C-terminus to RAD51AP1. Moreover, we demonstrated
previouslythatRAD51AP1alsointeractswithRAD51through
itsC-terminus(37).TofurtherdeﬁnetheregionofRAD51AP1
involved in RAD51-binding, the C-terminal fragments of
RAD51AP1 analogous to those of RAD51AP2 were tested
for their interaction with RAD51. In particular, fragments
RAD51AP1-C89 and RAD51AP1-C25 were used, which
roughly correspond to RAD51AP2-C92 and RAD51AP2-
C33, respectively. As shown in Table 2, RAD51AP1-C89
and RAD51AP1-C25 protein fragments are highly efﬁcient
in their interaction with RAD51. Both RAD51AP2-RAD51
and RAD51AP1-RAD51 interactions occur when the inserts
are in either orientation with regards to the Y2H vectors,
but are strongest when RAD51 is present as a Gal4-AD
fusion. Thus, RAD51AP2 and RAD51AP1 are both using
short sequences at their C-termini to bind to RAD51. This
conclusion is further supported by our mutational analysis of
the RAD51AP2/RAD51AP1 homology region (see below).
Conserved residues within the RAD51AP1 and
RAD51AP2 C-terminal regions facilitate
interaction with RAD51
Site-speciﬁc mutagenesis of residues in the C-terminal
domains of RAD51AP1 and RAD51AP2 was performed to
determine whether the residues shared in common by these
Figure 5. Sequence homology between the RAD51AP2 and RAD51AP1 and
mutational analysis of their shared RAD51-interacting motifs. (A) Amino
acid identities and similarities are indicated by dark blue and gray squares,
respectively. Just the C-terminal domains of RAD51AP1 and of RAD51AP2
are shown. Under the sequences are the original residues that were mutated by
site-directed mutagenesis. The underlined mutated residues significantly
reduce the interaction with RAD51 (see panels B and C). Species
abbreviations are as follows: Hs—Homo sapiens; Mm—Mus musculus;
Gg—Gallus gallus.( B) Interactions in the Y2H system between RAD51 (i.e.
pEG960) and both RAD51AP1 (i.e. pOK31, with all of RAD51AP1) and site-
specifically mutated RAD51AP1 (in pOK31). Results are the average from
three different colonies, with the standard error of the mean. (C) Interactions
in the Y2H system between RAD51 (i.e. pEG960) and both RAD51AP2 (i.e.
pDS439; pGBKT7-RAD51AP2-C33) and site-specifically mutated RA-
D51AP2 (in pDS439). Results are the average from two different colonies,
with the standard error of the mean. * Indicate P <0.05 and ** for P <0.001
using the student T-test. Please note: the Y190-ura
  Y2H strain was used in
these studies, and it gives lower b-galactosidase activity that the HF7c Y2H
strain used in Table 1 and 2, and in addition, the RAD51AP2-C33 construct is
in the pGBKT7 vector that also results in lower b-gal activity than similar
pGBT9-derived constructs. The negative control was the original empty
vector used for that construct, together with RAD51.
Table 2. C-terminal fragments of RAD51AP2 and RAD51AP1 proteins
interact with RAD51
Gal4 DBD
plasmid
Gal4 AD
plasmid
Gal4 DBD
protein
fusion
Gal4 AD
protein
fusion
Units of
b-galactosidase
a
pEG918 pOK42 RAD51 RAD51AP2-
C321
300.9
pEG918 pOK77 RAD51 RAD51AP2-
DC57
<0.5
pEG918 pOK40 RAD51 RAD51AP2-
C92
143.4
pOK76 pEG960 RAD51AP2-
C92
RAD51 521.0
pOK92 pEG960 RAD51AP2-
C33
RAD51 395.4
pEG918 pOK18 RAD51 RAD51AP1 111.0
pEG918 pOK35 RAD51 RAD51AP1-
C89
24.6
pOK31 pEG960 RAD51AP1 RAD51 590.3
pOK62 pEG960 RAD51AP1-
C89
RAD51 419.6
pOK81 pEG960 RAD51AP1-
C25
RAD51 473.3
aThe units of b-galactosidase are average values from at least four liquid
cultures.
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Eight residues in RAD51AP1-CTD were mutated
(Figure 5A), and four amino acid substitutions (R316A,
L319Q, L328A and H329A) signiﬁcantly decreased the
interaction with RAD51 in the Y2H system using both the
qualitative X-gal assay (data not shown) and the quantitative
ONPG assay for b-galactosidase activity (Figure 5B). In addi-
tion, the double mutant RAD51AP1-H329A/P330A and the
double L328/H329 deletion both showed decreased inter-
action with RAD51 to a similar extent as the individual
L328A and H329A mutations in the qualitative assay (data
not shown). Amino acid substitutions at other residues did
not affect the interaction with RAD51; the RAD51AP1-
R321A and -K326A substitutions in residues conserved
with human RAD51AP2 each had no signiﬁcant effect on
RAD51 interaction, nor did the RAD51AP1-L322S mutation
in a residue not conserved with RAD51AP2 (data not shown).
Amino acid substitutions in RAD51AP2 were made in
three residues that are conserved with RAD51AP1 and
that greatly reduced the RAD51AP1-RAD51 interaction. In
RAD51AP2, these amino acids changes (RAD51AP2-
L1134Q, -L1143A and -H1144A) all also greatly decreased
the interaction with RAD51 (Figure 5C). A stop codon
replacing RAD51AP2-Y1146 also signiﬁcantly decreased
the interaction with RAD51, but to a much lesser extent. It
seems reasonable to speculate that the Tyr-Leu-Lys residues
shared by human, mouse and chicken RAD51AP2 might be
important for full RAD51 interaction, although these residues
are not conserved in RAD51AP1.
Refined mapping of the region of human RAD54 that
interacts with RAD51
Amino acid sequence comparisons of the shared RAD51-
interacting motif (described above) with the sequence of
other RAD51-interacting partners revealed an interesting
sequence homology with human RAD54. In the most highly
conserved region shared by RAD51AP1 and RAD51AP2,
out of 16 amino acids, RAD54 shares 50% homology (six
identical residues and two conserved residues) (Figure 6A).
We have demonstrated previously that the human RAD54
protein interacts with human RAD51 through sequences
located within ﬁrst 142 residues of RAD54 (16). The region
of RAD54 that shares homology with RAD51AP1-CTD
and RAD51AP2-CTD is within this previously deﬁned
RAD51-interacting region.
The homology of human RAD54 96–111 with the
C-termini of RAD51AP2 and RAD51AP1 that facilitate the
interaction with RAD51 (Figure 6A) suggests that these
residues within RAD54-N142 may be critical for the inter-
action with RAD51. To test this, truncation mutations were
made from RAD54-N142. When tested in the Y2H system
for interaction with RAD51, RAD54-N89 gave between 25
and 32% as strong an interaction as full length RAD54-
N142 (Figure 6B and C). Since RAD54-N89 does not contain
any of the residues shared in common with RAD51AP1 and
RAD51AP2, it suggests that the conserved region is not
required to obtain signiﬁcant interaction between RAD54
and RAD51. In addition, RAD54 90–142 that contains the
complete conserved region, failed to interact with RAD51
(Figure 6B). On the other hand, there is some evidence
that this conserved region may play a role in increasing the
interaction with RAD51. e.g. RAD54-N118 fragment gave
a much stronger interaction than RAD54-N89. In addition,
a 40 amino acids fragment (RAD54 79–118) that completely
contains the conserved region gave  43% of the strength
of the RAD51 interaction with RAD54-N142. Two larger
fragments, each containing RAD54 79–118, but each also
including additional residues on one side or the other, both
give >70%, as compared to RAD54-N142. These results
Figure 6. Truncation mapping and mutational analysis of the human RAD54-RAD51 interaction. (A) Amino acid sequence homology between human RAD54
and the RAD51-interacting domains of RAD51AP1 and RAD51AP2. Amino acid identities and similarities are indicated by dark blue and gray squares,
respectively. Under the sequences are the original RAD54 residues that were mutated by site-directed mutagenesis. (B) PCR was used to make different
truncation constructs of RAD54-N142 (amino acids 1–142) in pGBT9, and these truncations were tested for interaction with RAD51 (pEG960) in the Y2H strain
Y190-ura
 . Results are the average from three different colonies, with the standard error of the mean shown. Only one colony of the negative control (pGBT9
with pEG918) was quantified, but similar negative controls always give about this same result. (C) Mutations were introduced into the N-terminal fragments of
RAD54 consisting of 142 or 89 residues (N142 and N89, respectively) and tested for their interaction with RAD51 in the two-hybrid system, using Y2H strain
HF7c. The P85A mutation was made in RAD54-N89, while all the rest were made in RAD54-N142. WT, wild-type sequence. For identical constructs, the Y2H
strain Y190-ura
  gives lower b-galactosidase activity that HF7c.
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79–118, but that there are additional residues on each side
that independently and additively increase the strength of
the interaction.
In addition, point mutations were introduced in RAD54
region 79–118, and analyzed in the two-hybrid system
(Figure 6C). Amino acid substitutions (RAD54-L109Q and
-H110A) in the very conserved Leu-His motif did not affect
the RAD54–RAD51 interaction at all, nor did a P112A
substitution (Figure 6C). However, we found that residues
N-terminal to the RAD51AP1/RAD51AP2 homology region
in RAD54 are important for the interaction with RAD51,
since RAD54-F82S and -P85A abolish the RAD51 inter-
action completely (Figure 6C).
In summary, both RAD51AP2 and RAD51AP1 use a
common sequence motif located near their C-termini for
RAD51-binding. In contrast, a similar sequence motif present
in the amino-terminus of RAD54 protein is not completely
critical for the interaction with RAD51. Instead, residues
closer to the amino-terminus of RAD54, such as F82 and
P85 located outside of the homologous region, seem to be
essential for the interaction with RAD51.
DISCUSSION
RAD51AP2 shares a conserved RAD51-binding motif
with RAD51AP1
We isolated a fragment of a previously unknown protein,
RAD51AP2, via its interaction with human RAD51 in a
Y2H library screen (Figure 1). The full length RAD51AP2
ORF was cloned and sequenced, and the sequence suggests
that the full-length protein is 1159 amino acid residues with
no signiﬁcant homology to any other protein, apart from its
C-terminal RAD51-interacting region. We provided evidence
that the interaction between RAD51AP2 and RAD51 is facili-
tated by a short sequence at the C-terminus of RAD51AP2
(Table 1), which displays strong homology (81% in a 16
amino acids region) to the C-terminal region of RAD51AP1
(Figure 5A), a previously identiﬁed 335 amino acids RAD51-
interacting protein (19,37). As with RAD51AP2, this conser-
ved motif in RAD51AP1 also comprises part of its interacting
region with RAD51 (Table 2). Among the 16 amino acids
spanning the highly homologous sequence motif between
human RAD51AP2 and RAD51AP1, 11 residues are identical
and two are highly conserved. We have not tested yet
whether this highly homologous sequence motif (16 amino
acids) is sufﬁcient for either the RAD51AP2–RAD51 or the
RAD51AP1–RAD51 interaction. However, our Y2H results
show that the longer 25 residue-encompassing C-terminal
region of RAD51AP1 and the last 33 residues in
RAD51AP2 (inclusive of a stretch of residues with no homo-
logy to RAD51AP1 at the very C-terminus—see Figure 5A)
are fully capable of interaction with RAD51. Interestingly, in
each gene, a relatively short C-terminal exon completely
encodes the RAD51-interacting region, and RAD51AP1 and
RAD51AP2 share no other region of homology.
Our Y2H results on site-speciﬁc mutations in both
RAD51AP1 and RAD51AP2 demonstrate that for both pro-
teins several of the highly conserved residues are crucially
important to maintain the interaction with RAD51. To the
best of our knowledge, RAD51AP1 and RAD51AP2 carry
the ﬁrst binding-motif for RAD51 that is commonly shared
by more than one of RAD51’s interacting partners. A some-
what similar situation exists for BRCA2 and its multiple BRC
repeats, since these repeats also bind to RAD51 via a
conserved sequence motif (20). However, the BRCA2-BRC
repeat sequence does not appear to be present in any
additional RAD51-interacting partner, although it does
share homology with a RAD51 self-interacting region (22).
We speculate that both RAD51AP1 and RAD51AP2
may interact with the same region on RAD51 via their
commonly shared homologous sequence motifs. If this
were the case, their simultaneous binding to a single
RAD51 monomer would be very unlikely. Since RAD51
forms both multimers and ﬁlaments, it is still possible that
RAD51AP1 and RAD51AP2 could potentially bind to
adjacent or nearby RAD51 monomers. As discussed
below, RAD51AP2 appears not to be expressed in mitotic
cells, but since RAD51, RAD51AP1 and RAD51AP2 are all
expressed in meiosis simultaneous interactions could still
occur in meiotic cells.
At least 12 of the DNA replication- and repair-related
protein partners that interact with PCNA (proliferating cell
nuclear antigen) also utilize a conserved motif, but different
from the RAD51-binding motif described here (41). In our
study, a highly conserved RAD51-binding motif has been
identiﬁed, but it appears to be present in only two different
human proteins (RAD51AP1 and RAD51AP2), with the
possible exception of RAD54 (discussed below). Unlike the
RAD51-binding motif, the PCNA-binding motif is ancient
and conserved to archaea and bacteriophages (41). None-
theless, it still is possible that an ancestral RAD51- or
RecA-binding motif may exist that is related to the motif
described here, but that the ancestral motif is insufﬁciently
conserved to be recognizable.
RAD54 shares limited homology with the identified
RAD51-binding motif
While attempting to identify other previously known partners
of RAD51 that may carry a sequence motif with some homo-
logy to the conserved motif in RAD51AP1/RAD51AP2, we
identiﬁed RAD54, which shares 50% homology within the
16 amino acids core region. Previously, we already reported
that the N-terminal region of human RAD54 (amino acids
1–142) facilitates binding to RAD51 (16). Our sequence
alignment (Figure 6A) shows that amino acids 96–111,
embedded within this N-terminal region of RAD54, display
signiﬁcant homology to the conserved binding-motif in
RAD51AP1/RAD51AP2. However, the results from the
Y2H experiments also suggest that in RAD54 amino acids
1–89 are sufﬁcient to convey a strong interaction with
RAD51 (Figure 6B and C), indicating that the residues with
homology (amino acids 96–111) to the conserved RAD51-
interacting motif in RAD51AP1/RAD51AP2 are not required
for the RAD54–RAD51 interaction. In addition, two key
residues in the N-terminal region of RAD54 located upstream
of the homologous region appear to be important for its inter-
action with RAD51 (Figure 6C). Conversely, several residues
within the amino acids 96–111 region appear not to be
involved in the RAD54–RAD51 interaction. However,
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system we obtained evidence that amino acids 96–111 may
play a secondary role in enhancing the interaction between
RAD54 and RAD51 (Figure 6B and C). Additionally, an
extensive N-terminal domain of RAD54 appears to be
required to obtain full interaction strength with RAD51 in
the Y2H system (Figure 6B). Our results suggest that the
interaction between RAD54 and RAD51 may involve either
a large interface or a series of multiple shorter interfaces.
RAD54 has been postulated to play an important role in
many stages of HRR (42), and its interaction with RAD51
in human cells is very likely to be required for at least
some of these activities.
The interaction between RAD51 and the N-terminal
domain of RAD54 has also been observed in the yeast
S.cerevisiae (43,44). In recent in vitro experiments, the direct
RAD51–RAD54 interaction has been shown to be important
for RAD54 enhancing the DNA pairing reaction mediated by
RAD51 (45). This paper also reported that RAD51 stimulates
both the RAD54 ATPase activity and the ability of RAD54 to
introduce superhelical tension into circular plasmid DNA,
and that these activities also depend on the RAD51–RAD54
direct interaction. This recent study also showed that there are
separable epitopes in RAD54 that interact with RAD51, in
accord with our speculations for an extensive RAD51–
RAD54 interface (see above). In our study however, the
region of homology between human RAD54 and both
RAD51AP1 and RAD51AP2 does not appear to be a separa-
ble interacting epitope in RAD54, since RAD54 amino acids
90–142 includes the entire homologous region but does not
by itself interact with human RAD51 (Figure 6B). It is
worth noting that the yeast RAD54 protein actually
shares two different regions with homology to the RAD51-
interacting region of human RAD54. One region of
ScRAD54 (amino acids 37–50, TKPFRVPYKNTHIP) shares
homology only with the HsRAD54 region that includes F82
and P85 (underlined F40 and P43 in ScRAD54), while the
second region of ScRAD54 (amino acids 129–164,
RSFTVPIKGYVQRHSLPLTLGMKKKITPEPRPLHDP)
shares homology with both the F82/P85 region and the
region with homology with RAD51AP1 and RAD51AP2
(our unpublished analysis).
The RAD51AP2 protein appears to be a meiotic partner
of RAD51
Among the 16 adult and 5 fetal tissues tested, we found that
the RAD51AP2 gene is expressed only in adult testis and fetal
ovary (Figures 2 and 3), indicating that RAD51AP2 is a
likely meiosis-speciﬁc partner of RAD51. No expression
was observed in adult ovary, where cells are arrested in
meiosis after recombination has been completed, nor was
expression observed in fetal testis, where cells have not yet
initiated meiosis. In addition, analyzing the enormous
human EST database, no human RAD51AP2 EST clones
have been identiﬁed from non-meiotic tissue, conﬁrming
our observation that RAD51AP2 seems to be expressed only
in cells undergoing meiosis. We also tested if RAD51AP2
might be expressed in mitotic cells after DNA damage, but
we found no such expression (Figure 3F). This was not
unexpected, since even those DNA repair genes induced by
DNA damage are normally constitutively expressed at a
detectable level. It is virtually impossible to prove that
RAD51AP2, or any gene for that matter, is never expressed
in any mitotic human cells, but our data strongly supports
this view.
Although RAD51AP2 does not appear to be expressed in
mitotic cells, our data show that an ectopically expressed
recombinant RAD51AP2 fragment is capable of interacting
with endogenous RAD51 in vivo (Figure 4). In addition,
this interaction is stimulated  7- and  17-fold after exposure
to the DNA-damaging agents MMC and MMS, respectively.
Both exposure to MMC and to MMS produces DSBs that are
repaired by HRR mediated by RAD51, and DSBs also are
produced endogenously during DNA replication and during
meiosis (7,8,12,36). The increase in the RAD51AP2–
RAD51 association after DNA damage may occur if both
proteins are targeted to the same locations within the nucleus,
e.g. DSBs and/or RAD51 foci. Alternatively, or concomi-
tantly, the RAD51–RAD51AP2 interaction may also be stabi-
lized via posttranslational protein modiﬁcation in response to
high levels of DNA damage. If RAD51AP2 is expressed only
during meiosis, as seems likely from our data, DNA damage
may mimic some aspect of meiosis such as the formation of
DSBs, and if this is the case, then RAD51AP2 may preferen-
tially interact with RAD51 when DSBs are present during
pachytene (6–8). Studying the interactions of an ectopically
overexpressed protein in mammalian cells can sometimes
lead to false positives, but we feel that this is not likely to
be the case here. Firstly, the in vivo interaction studies
conﬁrm a protein–protein interaction observed in the Y2H
system that is very strong and that occurs when the inserts
are in both orientations. Secondly, it seems rather unlikely
that a false-positive protein–protein interaction would be
stabilized by DNA damage, as was observed here.
Interestingly, the isolated RAD51AP2 amino acid
sequence does not interact in the Y2H system with DMC1,
a homolog of RAD51 that is meiotic speciﬁc (6–8) and
required for meiotic chromosome synapsis (46,47). The inter-
action of RAD51AP2 with other meiotic-speciﬁc proteins,
such as the SPO11 endonuclease and proteins involved in
the synaptonemal complex, has not been tested, but would
be worth testing.
RAD51-associated proteins frequently play an
important role in recombination
Much has been learned recently about RAD51 function and
regulation by studying its interacting partners. For example,
the interaction of RAD51 with TP53 has been shown to con-
trol the speciﬁcity of RAD51 in HRR (23). The interaction of
RAD51 with the BRCA2-BRC repeats have been postulated
to play a role in aligning multiple monomers of RAD51 and
then polymerizing them into a ﬁlament on ssDNA (48).
RAD51 interacts with a DNA-binding domain of RPA,
and this interaction has been postulated to help RAD51
displace RPA from ssDNA (33). Eventually understanding
the function and structure of the interactions of RAD51
with RAD51AP1 and with RAD51AP2 should give us impor-
tant information about HRR, meiotic recombination, and the
role of these new proteins. For example, while this manu-
script was in ﬁnal review, a study was published showing
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(49), ﬁndings that are in accord with our own unpublished
results (C. Wiese and D. Schild, manuscript in preparation).
In conclusion, RAD51AP2 has been identiﬁed as a
novel meiotic-speciﬁc RAD51-interacting protein, and
RAD51AP2 and RAD51AP1 share a common motif impor-
tant for RAD51-binding. The fact that RAD51AP1 and
RAD51AP2 are both vertebrate-speciﬁc suggest that
these proteins may potentially play a regulatory role in
recombination.
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